At GoeGoe Honglin Pharm., our R&D pipeline reflects our long-standing commitment to seeking truth from facts and contributing to society.

GoeGoe Honglin Pharm. not only masters preparation technologies such as sustained-release pellets, enteric-coated pellets, and double-layer sustained-release tablets, but also covers formulation types including compound and single-ingredient formulations, and further inherits the core technology from ALZA Corporation — the originator of osmotic pump controlled release technology.

This technology, known as OROS (Osmotic Controlled-Release Oral Delivery System), involved the osmotic design of the tablet’s core and membrane, which contained both the drug and osmotic agent. It’s an advanced drug delivery technology that controls the release rate of medications in tablet form. When a patient swallows an OROS tablet, water is drawn through the membrane to saturate the drug, which is then released in liquid form drop by drop through laser-drilled holes in the tablet. This permits a gradual release of the drug and leads to reduced side effects and predictable levels of the drug in the bloodstream.

Driven by the passion to contribute to the pharmaceutical industry, GoeGoe Honglin Pharm. has established a specialized overseas R&D team. Dr. Huang, one of the core members, holds a doctoral degree from the University of Michigan (U.S.A.) and has served successively in internationally renowned pharmaceutical giants such as Merck & Co., Inc. and ALZA Corporation, boasting profound technical accumulation and extensive industry experience. Furthermore, we have specially invited the patent inventor of the controlled-release technology to provide technical support, realizing the precise implementation and systematic inheritance of this core technology.

Notably, in recognition of GoeGoe Honglin Pharm.’s remarkable contributions to the inheritance of controlled-release technology and as an affirmation of our technical strength, ALZA Corporation has presented the world’s first fully automatic mechanical drilling machine used for controlled-release tablet testing to our company for commemoration. This gesture holds profound significance, further demonstrating GoeGoe Honglin Pharm.’s outstanding technical capabilities in the field.

After multiple generations of technological upgrades, we have established a controlled-release technology platform with independent R&D patents, developing controlled-release products that achieve zero-order rate release. These products feature more stable blood drug concentrations, more definite therapeutic effects, fewer side effects, and greater suitability for long-term use, making them a trusted choice among physicians and patients.